ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CV vs JNJ // GROSS PROFIT MARGIN

CapsoVision Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CV 2 — JNJ 8
▲ GROSS PROFIT MARGIN LEADER: JNJ
gross-margins
52.90%
gross-margins
67.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CV VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CV JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE 52.90% 67.90% -15.00 JNJ /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 25.50% -60.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield -6.22% 2.97% -9.19 JNJ /fcf-yield <GO>
Operating Margin -60.00% 34.70% -94.70 JNJ /operating-margins <GO>
Net Profit Margin -60.00% 28.50% -88.50 JNJ /net-margins <GO>
Revenue Growth (YoY) 15.30% 6.00% +9.30 CV /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 5.59 +20.41 CV /balance-sheet <GO>
Piotroski F-Score Quality 4/9 8/9 -4.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 54.0 62.1 -8.12 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $369.2M $662.49B -$662.12B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CV REV JNJ REV CV GROSS % JNJ GROSS % CV FCF JNJ FCF
FY 2025 $13.6M $94.19B 52.9% 67.9% -$23.0M $19.70B
FY 2024 $11.8M $88.82B 54.2% 69.1% -$20.2M $19.84B
FY 2023 — $85.16B — — — $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CV // BETA —
JNJ // BETA 1.08